Thymic Rebound and Marrow Uptake — After Lymphoma Treatment

No. Thymic rebound is a sign that your immune system is recovering, not that the lymphoma has returned. It happens when the thymus gland — suppressed during chemotherapy — starts growing back and becomes active again. Because the thymus sits in the same part of the chest where many lymphomas first appear, it can look alarming in a scan report. Your haemato-oncologist will look at the shape, the pattern, and your clinical picture before drawing any conclusion.

FDG — the radioactive glucose used in a PET scan — is absorbed by any metabolically active tissue, not only cancer. A recovering thymus is working hard to produce immune cells, and that work uses energy. The amount of uptake, the shape of the thymus on CT, and the timing after treatment all help your nuclear medicine physician recognise rebound rather than disease. A low, even signal in a triangular gland looks different from the irregular uptake of active lymphoma.

Diffuse marrow uptake is usually a sign that your bone marrow is recovering and producing new blood cells after chemotherapy. It is especially common in patients who received G-CSF injections. The key word is diffuse — spread evenly throughout the skeleton — as opposed to focal or patchy uptake, which would raise more concern. Your haemato-oncologist will read the full report and compare it with your previous scans before saying what it means for you.

The duration varies between individuals. Thymic rebound commonly appears within a few months of completing treatment and can persist for a year or longer in some young patients. It does not need treatment — it resolves on its own. If it is still present on a later scan, your team will note it in context rather than treating it as a new concern.

Sometimes. If the pattern is clearly consistent with rebound or marrow recovery, your haemato-oncologist may not need further imaging. If there is any uncertainty — for example, uptake in an unusual location or a pattern that does not clearly fit — a short-interval repeat scan or further investigation may be arranged. Your team will explain their reasoning either way. The decision to rescan is clinical, not something the scan report decides on its own.

Usually not, if the finding is confidently identified as rebound or recovery. Neither thymic rebound nor diffuse marrow uptake from bone marrow recovery requires additional treatment. What matters is that your haemato-oncologist reviews and documents the finding clearly, so it is not misread on future scans. If there is genuine uncertainty about whether some uptake represents residual disease, that discussion happens between you and your treating team before any decision is made.